Sekeres MA et al. Additional analyses of a randomized Phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup study SWOG S1117. Proc ASH 2015;Abstract 908.